Advertisement

Risk factors for recurrence of laryngeal amyloidosis treated by microforceps and CO2 laser

  • Xiufa Wu
  • Jing Zhang
  • Chunsheng WeiEmail author
Laryngology

Abstract

Introduction

Laryngeal amyloidosis is a benign, slowly progressive disease. The factors affecting the recurrence of LA have not been studied before for the rarity and incomplete understanding of this disease. To investigate the risk factors for the laryngeal amyloidosis treated by microforceps or carbon dioxide laser under microlaryngoscope, a retrospective review was conducted.

Materials and methods

One hundred and four patients (42 male and 72 female, with an average age of 51.3 years) with laryngeal amyloidosis were identified. The cases were collected from January 1989 to May 2014 at the Eye, Ear, Nose, and Throat Hospital of Fudan University.

Results

Seventy-five patients complained of hoarseness, 36 patients complained of hoarseness and dyspnea, and 3 patients complained of foreign body sensation. All patients underwent surgical removal of the amyloid deposits (via microforceps, CO2 laser and tracheotomy). Thirty patients developed recurrences requiring further treatments. The duration from onset to the treatment and age affected the recurrence of laryngeal amyloidosis, the surgery method, stenotic degree and stenotic area of subglottic area and trachea did not affect the recurrence of the disease.

Conclusion

Early diagnosis and treatment of laryngeal amyloidosis may reduce the recurrence of the disease. Regular follow-up is necessary to find any recurrence.

Keywords

Laryngeal amyloidosis Recurrence Hoarseness Treatment Selection and timing of operation Duration from onset to the treatment 

Notes

Acknowledgements

This study was supported by Science and Technology Commission of Shanghai Municipality.

Funding

Science and Technology Commission of Shanghai Municipality (CN) (Grant number: 18411965600).

Compliance with ethical standards

Conflict of interest

None of the authors has potential conflicts of interest. None of the authors has or has had any affiliation with any organization with a financial interest, direct or indirect, in the subject matter or materials discussed in the manuscript that may affect the conduct of reporting of the work submitted.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Barnes EL Jr, Zofar T (1977) Laryngeal amyloidosis, clinicopathologic study of seven cases. Ann Otol Rhinol Laryngol 86:856–862CrossRefGoogle Scholar
  2. 2.
    Finn DG, Farmer JC Jr (1982) Management of amyloidosis of the larynx and trachea. Arch Otolaryngol 108:54–56CrossRefGoogle Scholar
  3. 3.
    Ma L, Bandarchi B, Sasaki C, Levine S, Choi Y (2005) Primary localized laryngeal amyloidosis: report of 3 cases with longterm follow-up and review of the literature. Arch Pathol Lab Med 129:215–218PubMedGoogle Scholar
  4. 4.
    Thompson LDR, Derringer GA, Wenig BM (2000) Amyloidosis of the larynx: a clinicopathologic study of 11 cases. Mod Pathol 13:528–535CrossRefGoogle Scholar
  5. 5.
    Pribitkin E, Friedman O, O’Hara B et al (2003) Amyloidosis of the upper aerodigestive tract. Laryngoscope 113:2095–2101CrossRefGoogle Scholar
  6. 6.
    Simpson GT 2nd, Strong MS, Skinner M, Cohen AS (1984) Localised amyloidosis of the head and neck and the upper aerodigestive and lower respiratory tracts. Ann Otol Rhinol Laryngol 93:374–379CrossRefGoogle Scholar
  7. 7.
    Monnier P, Dikkers FG, Eckel H et al (2015) Preoperative assessment and classification of benign laryngotracheal stenosis: a consensus paper of the European Laryngological Society. Eur Arch Otorhinolaryngol 272:2885–2896CrossRefGoogle Scholar
  8. 8.
    Hazenberg AJ, Hazenberg BP, Dikkers FG (2016) Long-term follow-up after surgery in localized laryngeal amyloidosis. Eur Arch Otorhinolaryngol 273:2613–2620CrossRefGoogle Scholar
  9. 9.
    Graamans K, Lubsen H (1985) Clinical implications of laryngeal amyloidosis. J Laryngol Otol 99:617–623CrossRefGoogle Scholar
  10. 10.
    Lanks CW, Van Natta TL, Hsia DW (2016) Primary laryngotracheal amyloidosis with bilateral vocal cord involvement and associated bronchiectasis. J Bronchol Interv Pulmonol 23:347–349CrossRefGoogle Scholar
  11. 11.
    Hui AN, Koss MN, Hochholzer L, Wehunt WD (1986) Amyloidosis presenting in the lower respiratory tract. Clinicopathologic, radiologic, immunohistochemical, and histochemical studies on 48 cases. Arch Pathol Lab Med 110:212–218PubMedGoogle Scholar
  12. 12.
    Mares DC, Broderick LS, Cummings OW, Benson MD, Mathur PN (1998) Tracheobronchial amyloidosis: a review of clinical and radiographic characteristics, bronchoscopic diagnosis, and management. J Bronchol 5:147–155CrossRefGoogle Scholar
  13. 13.
    D’Aguanno V, Ralli M, Artico M et al (2019) Systemic amyloidosis: a contemporary overview. Clin Rev Allergy Immunol.  https://doi.org/10.1007/s12016-019-08759-4 CrossRefPubMedGoogle Scholar
  14. 14.
    Sawaya MR, Sambashivan S, Nelson R et al (2007) Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 447:453–457CrossRefGoogle Scholar
  15. 15.
    Iadanza MG, Jackson MP, Hewitt EW et al (2018) A new era for understanding amyloid structures and disease. Nat Rev Mol Cell Biol 19:755–773CrossRefGoogle Scholar
  16. 16.
    Berg AM, Troxler RF, Grillone G et al (1993) Localized amyloidosis of the larynx: evidence for light chain composition. Ann Otol Rhinol Laryngol 102:884–889CrossRefGoogle Scholar
  17. 17.
    Kourelis TV, Kyle RA, Dingli D et al (2007) Presentation and outcomes of localized immunoglobulin light chain amyloidosis: the mayo clinic experience. Mayo Clin Proc 92:908–917CrossRefGoogle Scholar
  18. 18.
    Hellquist H, Olofsson J, Sokjer H, Odkvist LM (1979) Amyloidosis of the larynx. Acta Otolaryngol 88:443–450CrossRefGoogle Scholar
  19. 19.
    Godbersen GS, Leh JF, Hansmann ML, Rudert H, Linke RP (1992) Organ-limited laryngeal amyloid deposits: clinical, morphological, and immunohistochemical results of five cases. Ann Otol Rhinol Laryngol 101:770–775CrossRefGoogle Scholar
  20. 20.
    Preud'homme JL, Ganeval D, Grünfeld JP, Striker L, Brouet JC (1988) Immunoglobin synthesis in primary and myeloma amyloidosis. Clin Exp Immunol 73:389–394PubMedPubMedCentralGoogle Scholar
  21. 21.
    Kennedy TL, Patel NM (2000) Surgical management of localized amyloidosis. Laryngoscope 110:918–923CrossRefGoogle Scholar
  22. 22.
    Piazza C, Cavaliere S, Foccoli P, Toninelli C, Bolzoni A, Peretti G (2003) Endoscopic management of laryngo-tracheobronchial amyloidosis: a series of 32 patients. Eur Arch Otorhinolaryngol 260:349–354CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Otolaryngology-Head and Neck SurgeryEye, Ear, Nose, and Throat Hospital of Fudan UniversityShanghaiPeople’s Republic of China
  2. 2.Department of Facial Plastic and Reconstructive SurgeryEye, Ear, Nose, and Throat Hospital of Fudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations